» Articles » PMID: 32932600

Mouse Ataxin-2 Expansion Downregulates CamKII and Other Calcium Signaling Factors, Impairing Granule-Purkinje Neuron Synaptic Strength

Abstract

Spinocerebellar ataxia type 2 (SCA2) is caused by polyglutamine expansion in Ataxin-2 (ATXN2). This factor binds RNA/proteins to modify metabolism after stress, and to control calcium (Ca) homeostasis after stimuli. Cerebellar ataxias and corticospinal motor neuron degeneration are determined by gain/loss in ATXN2 function, so we aimed to identify key molecules in this atrophic process, as potential disease progression markers. Our -CAG100-Knock-In mouse faithfully models features observed in patients at pre-onset, early and terminal stages. Here, its cerebellar global RNA profiling revealed downregulation of signaling cascades to precede motor deficits. Validation work at mRNA/protein level defined alterations that were independent of constant physiological ATXN2 functions, but specific for RNA/aggregation toxicity, and progressive across the short lifespan. The earliest changes were detected at three months among Ca channels/transporters (, , , , ), IP metabolism (, , ), and Ca-Calmodulin dependent kinases (, ). CaMKIV-Sam68 control over alternative splicing of , an adhesion component of glutamatergic synapses between granule and Purkinje neurons, was found to be affected. Systematic screening of pre/post-synapse components, with dendrite morphology assessment, suggested early impairment of CamKIIα abundance together with the weakening of parallel fiber connectivity. These data reveal molecular changes due to ATXN2 pathology, primarily impacting excitability and communication.

Citing Articles

Candidate SNP Markers Significantly Altering the Affinity of the TATA-Binding Protein for the Promoters of Human Genes Associated with Primary Open-Angle Glaucoma.

Zolotareva K, Dotsenko P, Podkolodnyy N, Ivanov R, Makarova A, Chadaeva I Int J Mol Sci. 2024; 25(23).

PMID: 39684516 PMC: 11641052. DOI: 10.3390/ijms252312802.


ATAXIN-2 intermediate-length polyglutamine expansions elicit ALS-associated metabolic and immune phenotypes.

Vieira de Sa R, Sudria-Lopez E, Canizares Luna M, Harschnitz O, van den Heuvel D, Kling S Nat Commun. 2024; 15(1):7484.

PMID: 39209824 PMC: 11362472. DOI: 10.1038/s41467-024-51676-0.


Ataxin-2: a powerful RNA-binding protein.

Li L, Wang M, Huang L, Zheng X, Wang L, Miao H Discov Oncol. 2024; 15(1):298.

PMID: 39039334 PMC: 11263328. DOI: 10.1007/s12672-024-01158-y.


The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.

Costa R, Conceicao A, Matos C, Nobrega C Cell Death Dis. 2024; 15(6):415.

PMID: 38877004 PMC: 11178924. DOI: 10.1038/s41419-024-06812-5.


Phenotypical, genotypical and pathological characterization of the moonwalker mouse, a model of ataxia.

Sekerkova G, Kilic S, Cheng Y, Fredrick N, Osmani A, Kim H Neurobiol Dis. 2024; 195:106492.

PMID: 38575093 PMC: 11089908. DOI: 10.1016/j.nbd.2024.106492.


References
1.
Pulst S, Nechiporuk A, Nechiporuk T, Gispert S, Chen X, Lopes-Cendes I . Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet. 1996; 14(3):269-76. DOI: 10.1038/ng1196-269. View

2.
Wang X, Chen X . A cytosolic network suppressing mitochondria-mediated proteostatic stress and cell death. Nature. 2015; 524(7566):481-4. PMC: 4582408. DOI: 10.1038/nature14859. View

3.
Ross O, Rutherford N, Baker M, Soto-Ortolaza A, Carrasquillo M, DeJesus-Hernandez M . Ataxin-2 repeat-length variation and neurodegeneration. Hum Mol Genet. 2011; 20(16):3207-12. PMC: 3140823. DOI: 10.1093/hmg/ddr227. View

4.
Iijima T, Hidaka C, Iijima Y . Spatio-temporal regulations and functions of neuronal alternative RNA splicing in developing and adult brains. Neurosci Res. 2016; 109:1-8. DOI: 10.1016/j.neures.2016.01.010. View

5.
Halbach M, Gispert S, Stehning T, Damrath E, Walter M, Auburger G . Atxn2 Knockout and CAG42-Knock-in Cerebellum Shows Similarly Dysregulated Expression in Calcium Homeostasis Pathway. Cerebellum. 2016; 16(1):68-81. PMC: 5243904. DOI: 10.1007/s12311-016-0762-4. View